Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 667 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib MOST POPULAR FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma August 30, 2021 “Supporting research is mission critical for me and always will be”... November 29, 2021 A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... August 16, 2021 John Cena Set The Record For Most Make-A-Wish Visits And He... March 4, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic... COVID-19 Vaccines: Considerations for Special Populations Happy Occupational Therapy Month Listening to Patient Narratives
